Gilead: Hepatitis-C Access Strategy (A)

Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of this was accomplished through generic licensing, which brought a $10,000/year treatment regimen down to $100! Should the company replicate that strategy for Hepatitis C? If so, how would its US Healthcare customers, who were paying $84,000 per patient, react? On the other hand, Gilead had to balance the interests of its shareholders, who paid $11 billion for an acquisition that led to the new Hepatitis C drug.

Collection: HBSP (USA)
Ref: HBS-515025-E
Format: PDF
Number of pages: 19
Publication Date: Oct 28, 2014
Language: English
Review date: Jan 13, 2020

What material is included in this case:

Other supplements

Description

Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of this was accomplished through generic licensing, which brought a $10,000/year treatment regimen down to $100! Should the company replicate that strategy for Hepatitis C? If so, how would its US Healthcare customers, who were paying $84,000 per patient, react? On the other hand, Gilead had to balance the interests of its shareholders, who paid $11 billion for an acquisition that led to the new Hepatitis C drug.
Read more
Year: Event Year Start:2013
Industry Setting: Industry Setting:Pharmaceuticals

Gilead: Hepatitis-C Access Strategy (A)

Options of use
Number of copies
- +
As low as €8.20

Are you interested in this product?

Add it to your favourites so that your institution can purchase it.
You'll be able to order once your profile has been validated.
Add to wishlist

Leave your rating

"Gilead: Hepatitis-C Access Strategy (A)"